News

Nanobiotix has extended its cash runway into early 2028 and tightened strategic alignment around its lead asset, JNJ-1900 (formerly...

Nanobiotix closed 2025 with a materially de-risked operating plan and a clearer development arc for its radioenhancer JNJ-1900 (formerly...

Connect Biopharma reported a cluster of catalysts around its IL-4Rα antibody rademikibart: rapid-onset bronchodilation in a phase 1 intravenous...

BioAtla has launched a formal strategic review and cost-cutting program while rethinking the pace and structure of its clinical...

Fortress Biotech is exiting 2025 and entering 2026 with a string of monetization events that reshape its balance sheet...

Cue Biopharma has appointed Lucinda Warren as interim president and CEO, effective March 26, 2026, following the departure of...

AnaptysBio will spin off its biopharma operations into First Tracks Biotherapeutics, expected to list as TRAX, with a target...

Humacyte reported fourth-quarter and full-year 2025 results and advanced multiple commercial and clinical fronts for its bioengineered vascular conduit,...

Instil Bio has halted development of AXN-2510 via its wholly owned subsidiary Axion Bio and terminated its related license...

Werewolf Therapeutics has begun a strategic alternatives process, retaining Piper Sandler to evaluate options that include a sale, merger,...